Abstract
Therapeutic monoclonal antibodies (mAbs) are mostly of the IgG class and constitute highly efficacious biopharmaceuticals for a wide range of clinical indications. Full-length IgG mAbs are large proteins that are subject to multiple posttranslational modifications (PTMs) during biosynthesis, purification, or storage, resulting in micro-heterogeneity. The production of recombinant mAbs in nonhuman cell lines may result in loss of structural fidelity and the generation of variants having altered stability, biological activities, and/or immunogenic potential. Additionally, even fully human therapeutic mAbs are of unique specificity, by design, and, consequently, of unique structure; therefore, structural elements may be recognized as non-self by individuals within an outbred human population to provoke an anti-therapeutic/anti-drug antibody (ATA/ADA) response. Consequently, regulatory authorities require that the structure of a potential mAb drug product is comprehensively characterized employing state-of-the-art orthogonal analytical technologies; the PTM profile may define a set of critical quality attributes (CQAs) for the drug product that must be maintained, employing quality by design parameters, throughout the lifetime of the drug. Glycosylation of IgG-Fc, at Asn297 on each heavy chain, is an established CQA since its presence and fine structure can have a profound impact on efficacy and safety. The glycoform profile of serum-derived IgG is highly heterogeneous while mAbs produced in mammalian cells in vitro is less heterogeneous and can be “orchestrated” depending on the cell line employed and the culture conditions adopted. Thus, the gross structure and PTM profile of a given mAb, established for the drug substance gaining regulatory approval, have to be maintained for the lifespan of the drug. This review outlines our current understanding of common PTMs detected in mAbs and endogenous IgG and the relationship between a variant’s structural attribute and its impact on clinical performance.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- ADA:
-
Anti-drug antibody
- ADCC:
-
Antibody-dependent cellular cytotoxicity
- AGE:
-
Advanced glycation end product
- APR:
-
Aggregation-prone region
- ATA:
-
Anti-therapeutic antibody
- CDR:
-
Complementarity-determining region
- CHO:
-
Chinese hamster ovary
- CQA:
-
Critical quality attribute
- FcγR:
-
Receptor for Fc portion of IgG
- NeuAc:
-
N-acetylneuraminic acid
- NeuGc:
-
N-glycolylneuraminic acid
- PD:
-
Pharmacodynamics
- PK:
-
Pharmacokinetics
- PTM:
-
Posttranslational modification
- QbD:
-
Quality by design
References
Ahmad S, Moinuddin AA (2012) Immunological studies on glycated human IgG. Life Sci 90(25–26):980–987. https://doi.org/10.1016/j.lfs.2012.05.002
Alt N, Zhang TY, Motchnik P, Taticek R, Quarmby V, Schlothauer T, Beck H, Emrich T, Harris RJ (2016) Determination of critical quality attributes for monoclonal antibodies using quality by design principles. Biologicals 44(5):291–305. https://doi.org/10.1016/j.biologicals.2016.06.005
Ambrogelly A, Gozo S, Katiyar A, Dellatore S, Kune Y, Bhat R, Sun J, Li N, Wang D, Nowak C, Neill A, Ponniah G, King C, Mason B, Beck A, Liu H (2018) Analytical comparability study of recombinant monoclonal antibody therapeutics. MAbs 10(4):513–538. https://doi.org/10.1080/19420862.2018.1438797
Antes B, Amon S, Rizzi A, Wiederkum S, Kainer M, Szolar O, Fido M, Kircheis R, Nechansky A (2007) Analysis of lysine clipping of a humanized Lewis-Y specific IgG antibody and its relation to Fc-mediated effector function. J Chromatogr B Analyt Technol Biomed Life Sci 852(1–2):250–256. https://doi.org/10.1016/j.jchromb.2007.01.024
Arnold JN, Wormald MR, Sim RB, Rudd PM, Dwek RA (2006) The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol 25:21–50
Arvinte T, Palais C, Green-Trexler E, Gregory S, Mach H, Narasimhan C, Shameem M (2013) Aggregation of biopharmaceuticals in human plasma and human serum: implications for drug research and development. MAbs 5(3):491–500. https://doi.org/10.4161/mabs.24245
Banks DD, Gadgil HS, Pipes GD, Bondarenko PV, Hobbs V, Scavezze JL, Kim J, Jiang XR, Mukku V, Dillon TM (2008) Removal of cysteinylation from an unpaired sulfhydryl in the variable region of a recombinant monoclonal IgG1 antibody improves homogeneity, stability, and biological activity. J Pharm Sci 97(2):775–790. https://doi.org/10.1002/jps.21014
Banks DD, Hambly DM, Scavezze JL, Siska CC, Stackhouse NL, Gadgil HS (2009) The effect of sucrose hydrolysis on the stability of protein therapeutics during accelerated formulation studies. J Pharm Sci 98(12):4501–4510. https://doi.org/10.1002/jps.21749
Barb AW, Brady EK, Prestegard JH (2009) Branch-specific sialylation of IgG-Fc glycans by ST6Gal-I. Biochemistry 48(41):9705–9707. https://doi.org/10.1021/bi901430h
Beck A, Liu H (2019) Macro- and micro-heterogeneity of natural and recombinant IgG antibodies. Antibodies (Basel) 8(1):18. https://doi.org/10.3390/antib8010018
Bertolotti-Ciarlet A, Wang W, Lownes R, Pristatsky P, Fang Y, McKelvey T, Li Y, Li Y, Drummond J, Prueksaritanont T, Vlasak J (2009) Impact of methionine oxidation on the binding of human IgG1 to Fc Rn and Fc gamma receptors. Mol Immunol 46(8–9):1878–1882. https://doi.org/10.1016/j.molimm.2009.02.002
Butko M, Pallat H, Cordoba A, Yu XC (2014) Recombinant antibody color resulting from advanced glycation end product modifications. Anal Chem 86(19):9816–9823. https://doi.org/10.1021/ac5024099
Cai B, Pan H, Flynn GC (2011) C-terminal lysine processing of human immunoglobulin G2 heavy chain in vivo. Biotechnol Bioeng 108(2):404–412. https://doi.org/10.1002/bit.22933
Chaderjian WB, Chin ET, Harris RJ, Etcheverry TM (2005) Effect of copper sulfate on performance of a serum-free CHO cell culture process and the level of free thiol in the recombinant antibody expressed. Biotechnol Prog 21(2):550–553. https://doi.org/10.1021/bp0497029
Chelius D, Rehder DS, Bondarenko PV (2005) Identification and characterization of deamidation sites in the conserved regions of human immunoglobulin gamma antibodies. Anal Chem 77(18):6004–6011. https://doi.org/10.1021/ac050672d
Chelius D, Jing K, Lueras A, Rehder DS, Dillon TM, Vizel A, Rajan RS, Li T, Treuheit MJ, Bondarenko PV (2006) Formation of pyroglutamic acid from N-terminal glutamic acid in immunoglobulin gamma antibodies. Anal Chem 78(7):2370–2376. https://doi.org/10.1021/ac051827k
Cheng HD, Tirosh I, de Haan N, Stockmann H, Adamczyk B, McManus CA, O’Flaherty R, Greville G, Saldova R, Bonilla FA, Notarangelo LD, Driessen GJ, Holm IA, Rudd PM, Wuhrer M, Ackerman ME, Nigrovic PA (2020) IgG Fc glycosylation as an axis of humoral immunity in childhood. J Allergy Clin Immunol 145(2):710–713.e719. https://doi.org/10.1016/j.jaci.2019.10.012
Chennamsetty N, Helk B, Voynov V, Kayser V, Trout BL (2009a) Aggregation-prone motifs in human immunoglobulin G. J Mol Biol 391(2):404–413. https://doi.org/10.1016/j.jmb.2009.06.028
Chennamsetty N, Voynov V, Kayser V, Helk B, Trout BL (2009b) Design of therapeutic proteins with enhanced stability. Proc Natl Acad Sci U S A 106(29):11937–11942. https://doi.org/10.1073/pnas.0904191106
Chicooree N, Unwin RD, Griffiths JR (2015) The application of targeted mass spectrometry-based strategies to the detection and localization of post-translational modifications. Mass Spectrom Rev 34(6):595–626. https://doi.org/10.1002/mas.21421
Chumsae C, Gaza-Bulseco G, Sun J, Liu H (2007) Comparison of methionine oxidation in thermal stability and chemically stressed samples of a fully human monoclonal antibody. J Chromatogr B Analyt Technol Biomed Life Sci 850(1–2):285–294. https://doi.org/10.1016/j.jchromb.2006.11.050
Chumsae C, Gaza-Bulseco G, Liu H (2009) Identification and localization of unpaired cysteine residues in monoclonal antibodies by fluorescence labeling and mass spectrometry. Anal Chem 81(15):6449–6457. https://doi.org/10.1021/ac900815z
Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, Murphy BA, Satinover SM, Hosen J, Mauro D, Slebos RJ, Zhou Q, Gold D, Hatley T, Hicklin DJ, Platts-Mills TA (2008) Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 358(11):1109–1117. https://doi.org/10.1056/NEJMoa074943
Davies AM, Rispens T, den Bleker TH, McDonnell JM, Gould HJ, Aalberse RC, Sutton BJ (2013) Crystal structure of the human IgG4 C(H)3 dimer reveals the role of Arg409 in the mechanism of Fab-arm exchange. Mol Immunol 54(1):1–7. https://doi.org/10.1016/j.molimm.2012.10.029
de Haan N, Falck D, Wuhrer M (2020) Monitoring of immunoglobulin N- and O-glycosylation in health and disease. Glycobiology 30(4):226–240. https://doi.org/10.1093/glycob/cwz048
Dick LW Jr, Kim C, Qiu D, Cheng KC (2007) Determination of the origin of the N-terminal pyro-glutamate variation in monoclonal antibodies using model peptides. Biotechnol Bioeng 97(3):544–553. https://doi.org/10.1002/bit.21260
Dick LW Jr, Qiu D, Mahon D, Adamo M, Cheng KC (2008) C-terminal lysine variants in fully human monoclonal antibodies: investigation of test methods and possible causes. Biotechnol Bioeng 100(6):1132–1143. https://doi.org/10.1002/bit.21855
Dillon TM, Ricci MS, Vezina C, Flynn GC, Liu YD, Rehder DS, Plant M, Henkle B, Li Y, Deechongkit S, Varnum B, Wypych J, Balland A, Bondarenko PV (2008) Structural and functional characterization of disulfide isoforms of the human IgG2 subclass. J Biol Chem 283(23):16206–16215. https://doi.org/10.1074/jbc.M709988200
Dunn-Walters D, Boursier L, Spencer J (2000) Effect of somatic hypermutation on potential N-glycosylation sites in human immunoglobulin heavy chain variable regions. Mol Immunol 37(3–4):107–113
Edelman GM, Cunningham BA, Gall WE, Gottlieb PD, Rutishauser U, Waxdal MJ (1969) The covalent structure of an entire gammaG immunoglobulin molecule. Proc Natl Acad Sci U S A 63(1):78–85. https://doi.org/10.1073/pnas.63.1.78
Ewert S, Huber T, Honegger A, Pluckthun A (2003) Biophysical properties of human antibody variable domains. J Mol Biol 325(3):531–553. https://doi.org/10.1016/s0022-2836(02)01237-8
Fischer S, Hoernschemeyer J, Mahler HC (2008) Glycation during storage and administration of monoclonal antibody formulations. Eur J Pharm Biopharm 70(1):42–50. https://doi.org/10.1016/j.ejpb.2008.04.021
Gadgil HS, Bondarenko PV, Pipes G, Rehder D, McAuley A, Perico N, Dillon T, Ricci M, Treuheit M (2007) The LC/MS analysis of glycation of IgG molecules in sucrose containing formulations. J Pharm Sci 96(10):2607–2621. https://doi.org/10.1002/jps.20966
Gala FA, Morrison SL (2004) V region carbohydrate and antibody expression. J Immunol 172(9):5489–5494
Galili U, Anaraki F, Thall A, Hill-Black C, Radic M (1993) One percent of human circulating B lymphocytes are capable of producing the natural anti-Gal antibody. Blood 82(8):2485–2493
Gaza-Bulseco G, Faldu S, Hurkmans K, Chumsae C, Liu H (2008) Effect of methionine oxidation of a recombinant monoclonal antibody on the binding affinity to protein A and protein G. J Chromatogr B Analyt Technol Biomed Life Sci 870(1):55–62. https://doi.org/10.1016/j.jchromb.2008.05.045
Geiger T, Clarke S (1987) Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides. Succinimide-linked reactions that contribute to protein degradation. J Biol Chem 262(2):785–794
Goetze AM, Liu YD, Arroll T, Chu L, Flynn GC (2012) Rates and impact of human antibody glycation in vivo. Glycobiology 22(2):221–234. https://doi.org/10.1093/glycob/cwr141
Grey AA, Narasimhan S, Brisson JR, Schachter H, Carver JP (1982) Structure of the glycopeptides of a human gamma 1-immunoglobulin G (Tem) myeloma protein as determined by 360-megahertz nuclear magnetic resonance spectroscopy. Can J Biochem 60(12):1123–1131
Gu S, Wen D, Weinreb PH, Sun Y, Zhang L, Foley SF, Kshirsagar R, Evans D, Mi S, Meier W, Pepinsky RB (2010) Characterization of trisulfide modification in antibodies. Anal Biochem 400(1):89–98. https://doi.org/10.1016/j.ab.2010.01.019
Gudelj I, Lauc G, Pezer M (2018) Immunoglobulin G glycosylation in aging and diseases. Cell Immunol 333:65–79. https://doi.org/10.1016/j.cellimm.2018.07.009
Hafkenscheid L, Bondt A, Scherer HU, Huizinga TW, Wuhrer M, Toes RE, Rombouts Y (2017) Structural analysis of variable domain glycosylation of anti-citrullinated protein antibodies in rheumatoid arthritis reveals the presence of highly sialylated glycans. Mol Cell Proteomics 16(2):278–287. https://doi.org/10.1074/mcp.M116.062919
Hafkenscheid L, de Moel E, Smolik I, Tanner S, Meng X, Jansen BC, Bondt A, Wuhrer M, Huizinga TWJ, Toes REM, El-Gabalawy H, Scherer HU (2019) N-linked glycans in the variable domain of IgG anti-citrullinated protein antibodies predict the development of rheumatoid arthritis. Arthritis Rheumatol 71(10):1626–1633. https://doi.org/10.1002/art.40920
Harris RJ (1995) Processing of C-terminal lysine and arginine residues of proteins isolated from mammalian cell culture. J Chromatogr A 705(1):129–134. https://doi.org/10.1016/0021-9673(94)01255-d
Harris RJ (2005) Heterogeneity of recombinant antibodies: linking structure to function. Dev Biol (Basel) 122:117–127
Harris RJ, Kabakoff B, Macchi FD, Shen FJ, Kwong M, Andya JD, Shire SJ, Bjork N, Totpal K, Chen AB (2001) Identification of multiple sources of charge heterogeneity in a recombinant antibody. J Chromatogr B Biomed Sci Appl 752(2):233–245. https://doi.org/10.1016/s0378-4347(00)00548-x
Hmiel LK, Brorson KA, Boyne MT 2nd (2015) Post-translational structural modifications of immunoglobulin G and their effect on biological activity. Anal Bioanal Chem 407(1):79–94. https://doi.org/10.1007/s00216-014-8108-x
Holland M, Yagi H, Takahashi N, Kato K, Savage CO, Goodall DM, Jefferis R (2006) Differential glycosylation of polyclonal IgG, IgG-Fc and IgG-Fab isolated from the sera of patients with ANCA-associated systemic vasculitis. Biochim Biophys Acta 1760(4):669–677
Hu Z, Tang D, Misaghi S, Jiang G, Yu C, Yim M, Shaw D, Snedecor B, Laird MW, Shen A (2017) Evaluation of heavy chain C-terminal deletions on productivity and product quality of monoclonal antibodies in Chinese hamster ovary (CHO) cells. Biotechnol Prog 33(3):786–794. https://doi.org/10.1002/btpr.2444
Huang L, Lu J, Wroblewski VJ, Beals JM, Riggin RM (2005) In vivo deamidation characterization of monoclonal antibody by LC/MS/MS. Anal Chem 77(5):1432–1439. https://doi.org/10.1021/ac0494174
Huh JH, White AJ, Brych SR, Franey H, Matsumura M (2013) The identification of free cysteine residues within antibodies and a potential role for free cysteine residues in covalent aggregation because of agitation stress. J Pharm Sci 102(6):1701–1711. https://doi.org/10.1002/jps.23505
Hutterer KM, Hong RW, Lull J, Zhao X, Wang T, Pei R, Le ME, Borisov O, Piper R, Liu YD, Petty K, Apostol I, Flynn GC (2013) Monoclonal antibody disulfide reduction during manufacturing: untangling process effects from product effects. MAbs 5(4):608–613. https://doi.org/10.4161/mabs.24725
Jefferis R (2009) Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov 8(3):226–234. https://doi.org/10.1038/nrd2804
Jefferis R (2016) Posttranslational modifications and the immunogenicity of biotherapeutics. J Immunol Res 2016:5358272. https://doi.org/10.1155/2016/5358272
Jefferis R (2017a) Antibody posttranslational modifications. In: Liu C, Morrow KJJ (eds) Biosimilars of monoclonal antibodies: a practical guide to manufacturing, preclinical, and clinical development. Wiley, Chichester, pp 155–199. https://doi.org/10.1002/9781118940648
Jefferis R (2017b) Characterization of biosimilar biologics: the link between structure and functions. In: Endrenyi L, Declerck P, Chow S-C (eds) Drugs and the pharmaceutical sciences, vol 216. CRC Press, Boca Raton, pp 109–149
Jefferis R (2017c) Recombinant proteins and monoclonal antibodies. Adv Biochem Eng Biotechnol. https://doi.org/10.1007/10_2017_32
Jefferis R, Lund J, Mizutani H, Nakagawa H, Kawazoe Y, Arata Y, Takahashi N (1990) A comparative study of the N-linked oligosaccharide structures of human IgG subclass proteins. Biochem J 268(3):529–537
Jiang G, Yu C, Yadav DB, Hu Z, Amurao A, Duenas E, Wong M, Iverson M, Zheng K, Lam X, Chen J, Vega R, Ulufatu S, Leddy C, Davis H, Shen A, Wong PY, Harris R, Wang YJ, Li D (2016) Evaluation of heavy-chain C-terminal deletion on product quality and pharmacokinetics of monoclonal antibodies. J Pharm Sci 105(7):2066–2072. https://doi.org/10.1016/j.xphs.2016.04.027
Johnson KA, Paisley-Flango K, Tangarone BS, Porter TJ, Rouse JC (2007) Cation exchange-HPLC and mass spectrometry reveal C-terminal amidation of an IgG1 heavy chain. Anal Biochem 360(1):75–83. https://doi.org/10.1016/j.ab.2006.10.012
Kabat EA, Wu TT, Perry HM, Gottesman KS, Foeller C (1991) Sequences of proteins of immunological interest, 5th edn. NIH Publication, National Institutes of Health, Bethesda, MD
Kaschak T, Boyd D, Lu F, Derfus G, Kluck B, Nogal B, Emery C, Summers C, Zheng K, Bayer R, Amanullah A, Yan B (2011) Characterization of the basic charge variants of a human IgG1: effect of copper concentration in cell culture media. MAbs 3(6):577–583. https://doi.org/10.4161/mabs.3.6.17959
Kempers AC, Hafkenscheid L, Scherer HU, Toes REM (2018) Variable domain glycosylation of ACPA-IgG: a missing link in the maturation of the ACPA response? Clin Immunol 186:34–37. https://doi.org/10.1016/j.clim.2017.09.001
Kepert JF, Cromwell M, Engler N, Finkler C, Gellermann G, Gennaro L, Harris R, Iverson R, Kelley B, Krummen L, McKnight N, Motchnik P, Schnaible V, Taticek R (2016) Establishing a control system using QbD principles. Biologicals 44(5):319–331. https://doi.org/10.1016/j.biologicals.2016.06.003
Khawli LA, Goswami S, Hutchinson R, Kwong ZW, Yang J, Wang X, Yao Z, Sreedhara A, Cano T, Tesar D, Nijem I, Allison DE, Wong PY, Kao YH, Quan C, Joshi A, Harris RJ, Motchnik P (2010) Charge variants in IgG1: isolation, characterization, in vitro binding properties and pharmacokinetics in rats. MAbs 2(6):613–624. https://doi.org/10.4161/mabs.2.6.13333
Kita A, Ponniah G, Nowak C, Liu H (2016) Characterization of cysteinylation and trisulfide bonds in a recombinant monoclonal antibody. Anal Chem 88(10):5430–5437. https://doi.org/10.1021/acs.analchem.6b00822
Koterba KL, Borgschulte T, Laird MW (2012) Thioredoxin 1 is responsible for antibody disulfide reduction in CHO cell culture. J Biotechnol 157(1):261–267. https://doi.org/10.1016/j.jbiotec.2011.11.009
Kroon DJ, Baldwin-Ferro A, Lalan P (1992) Identification of sites of degradation in a therapeutic monoclonal antibody by peptide mapping. Pharm Res 9(11):1386–1393. https://doi.org/10.1023/a:1015894409623
Kshirsagar R, McElearney K, Gilbert A, Sinacore M, Ryll T (2012) Controlling trisulfide modification in recombinant monoclonal antibody produced in fed-batch cell culture. Biotechnol Bioeng 109(10):2523–2532. https://doi.org/10.1002/bit.24511
Lacy ER, Baker M, Brigham-Burke M (2008) Free sulfhydryl measurement as an indicator of antibody stability. Anal Biochem 382(1):66–68. https://doi.org/10.1016/j.ab.2008.07.016
Lakbub JC, Clark DF, Shah IS, Zhu Z, Go EP, Tolbert TJ, Desaire H (2016) Disulfide bond characterization of endogenous IgG3 monoclonal antibodies using LC-MS: an investigation of IgG3 disulfide-mediated isoforms. Anal Methods 8(31):6046–6055. https://doi.org/10.1039/C6AY01248E
Lewis DA, Guzzetta AW, Hancock WS, Costello M (1994) Characterization of humanized anti-TAC, an antibody directed against the interleukin 2 receptor, using electrospray ionization mass spectrometry by direct infusion, LC/MS, and MS/MS. Anal Chem 66(5):585–595. https://doi.org/10.1021/ac00077a003
Li W, Prabakaran P, Chen W, Zhu Z, Feng Y, Dimitrov DS (2016) Antibody aggregation: insights from sequence and structure. Antibodies (Basel) 5(3):19. https://doi.org/10.3390/antib5030019
Liu H, May K (2012) Disulfide bond structures of IgG molecules: structural variations, chemical modifications and possible impacts to stability and biological function. MAbs 4(1):17–23. https://doi.org/10.4161/mabs.4.1.18347
Liu H, Gaza-Bulseco G, Chumsae C (2008) Glutamine deamidation of a recombinant monoclonal antibody. Rapid Commun Mass Spectrom 22(24):4081–4088. https://doi.org/10.1002/rcm.3831
Liu YD, van Enk JZ, Flynn GC (2009) Human antibody Fc deamidation in vivo. Biologicals 37(5):313–322. https://doi.org/10.1016/j.biologicals.2009.06.001
Liu YD, Goetze AM, Bass RB, Flynn GC (2011) N-terminal glutamate to pyroglutamate conversion in vivo for human IgG2 antibodies. J Biol Chem 286(13):11211–11217. https://doi.org/10.1074/jbc.M110.185041
Lu RM, Hwang YC, Liu IJ, Lee CC, Tsai HZ, Li HJ, Wu HC (2020) Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci 27(1):1. https://doi.org/10.1186/s12929-019-0592-z
Luo S, Zhang B (2015) Dextrose-mediated aggregation of therapeutic monoclonal antibodies in human plasma: implication of isoelectric precipitation of complement proteins. MAbs 7(6):1094–1103. https://doi.org/10.1080/19420862.2015.1087636
Martinez T, Guo A, Allen MJ, Han M, Pace D, Jones J, Gillespie R, Ketchem RR, Zhang Y, Balland A (2008) Disulfide connectivity of human immunoglobulin G2 structural isoforms. Biochemistry 47(28):7496–7508. https://doi.org/10.1021/bi800576c
McCann KJ, Ottensmeier CH, Callard A, Radcliffe CM, Harvey DJ, Dwek RA, Rudd PM, Sutton BJ, Hobby P, Stevenson FK (2008) Remarkable selective glycosylation of the immunoglobulin variable region in follicular lymphoma. Mol Immunol 45(6):1567–1572
Miller AK, Hambly DM, Kerwin BA, Treuheit MJ, Gadgil HS (2011) Characterization of site-specific glycation during process development of a human therapeutic monoclonal antibody. J Pharm Sci 100(7):2543–2550. https://doi.org/10.1002/jps.22504
Mimura Y, Jefferis R (2021) Human IgG glycosylation in inflammation and inflammatory disease. In: Barchi JJ (ed) Comprehensive glycoscience, vol 5, 2nd edn. Elsevier, pp 215–232
Mimura Y, Kabat EA, Tanaka T, Fujimoto M, Takeo K, Nakamura K (1995) Microheterogeneity of mouse antidextran monoclonal antibodies. Electrophoresis 16(1):116–123. https://doi.org/10.1002/elps.1150160121
Mimura Y, Nakamura K, Tanaka T, Fujimoto M (1998) Evidence of intra- and extracellular modifications of monoclonal IgG polypeptide chains generating charge heterogeneity. Electrophoresis 19(5):767–775. https://doi.org/10.1002/elps.1150190528
Mimura Y, Jefferis R, Mimura-Kimura Y, Abrahams J, Rudd PM (2009) Glycosylation of therapeutic IgGs. In: An Z (ed) Therapeutic monoclonal antibodies: from the bench to the clinic. Wiley, Hoboken, pp 67–89
Mimura Y, Katoh T, Saldova R, O’Flaherty R, Izumi T, Mimura-Kimura Y, Utsunomiya T, Mizukami Y, Yamamoto K, Matsumoto T, Rudd PM (2018) Glycosylation engineering of therapeutic IgG antibodies: challenges for the safety, functionality and efficacy. Protein Cell 9(1):47–62. https://doi.org/10.1007/s13238-017-0433-3
Mo J, Jin R, Yan Q, Sokolowska I, Lewis MJ, Hu P (2018) Quantitative analysis of glycation and its impact on antigen binding. MAbs 10(3):406–415. https://doi.org/10.1080/19420862.2018.1438796
Montesino R, Calvo L, Vallin A, Rudd PM, Harvey DJ, Cremata JA (2012) Structural characterization of N-linked oligosaccharides on monoclonal antibody Nimotuzumab through process development. Biologicals 40(4):288–298. https://doi.org/10.1016/j.biologicals.2012.04.005
Nose M, Wigzell H (1983) Biological significance of carbohydrate chains on monoclonal antibodies. Proc Natl Acad Sci U S A 80(21):6632–6636
Ouellette D, Alessandri L, Chin A, Grinnell C, Tarcsa E, Radziejewski C, Correia I (2010) Studies in serum support rapid formation of disulfide bond between unpaired cysteine residues in the VH domain of an immunoglobulin G1 molecule. Anal Biochem 397(1):37–47. https://doi.org/10.1016/j.ab.2009.09.027
Pan H, Chen K, Chu L, Kinderman F, Apostol I, Huang G (2009) Methionine oxidation in human IgG2 Fc decreases binding affinities to protein A and FcRn. Protein Sci 18(2):424–433. https://doi.org/10.1002/pro.45
Pang Y, Wang WH, Reid GE, Hunt DF, Bruening ML (2015) Pepsin-containing membranes for controlled monoclonal antibody digestion prior to mass spectrometry analysis. Anal Chem 87(21):10942–10949. https://doi.org/10.1021/acs.analchem.5b02739
Parekh R, Roitt I, Isenberg D, Dwek R, Rademacher T (1988) Age-related galactosylation of the N-linked oligosaccharides of human serum IgG. J Exp Med 167(5):1731–1736
Pound JD, Lund J, Jefferis R (1993) Aglycosylated chimaeric human IgG3 can trigger the human phagocyte respiratory burst. Mol Immunol 30(3):233–241
Pristatsky P, Cohen SL, Krantz D, Acevedo J, Ionescu R, Vlasak J (2009) Evidence for trisulfide bonds in a recombinant variant of a human IgG2 monoclonal antibody. Anal Chem 81(15):6148–6155. https://doi.org/10.1021/ac9006254
Pucic M, Knezevic A, Vidic J, Adamczyk B, Novokmet M, Polasek O, Gornik O, Supraha-Goreta S, Wormald MR, Redzic I, Campbell H, Wright A, Hastie ND, Wilson JF, Rudan I, Wuhrer M, Rudd PM, Josic D, Lauc G (2011) High throughput isolation and glycosylation analysis of IgG-variability and heritability of the IgG glycome in three isolated human populations. Mol Cell Proteomics 10(10):M111 010090. https://doi.org/10.1074/mcp.M111.010090
Qian J, Liu T, Yang L, Daus A, Crowley R, Zhou Q (2007) Structural characterization of N-linked oligosaccharides on monoclonal antibody cetuximab by the combination of orthogonal matrix-assisted laser desorption/ionization hybrid quadrupole-quadrupole time-of-flight tandem mass spectrometry and sequential enzymatic digestion. Anal Biochem 364(1):8–18
Quan C, Alcala E, Petkovska I, Matthews D, Canova-Davis E, Taticek R, Ma S (2008) A study in glycation of a therapeutic recombinant humanized monoclonal antibody: where it is, how it got there, and how it affects charge-based behavior. Anal Biochem 373(2):179–191. https://doi.org/10.1016/j.ab.2007.09.027
Radcliffe CM, Arnold JN, Suter DM, Wormald MR, Harvey DJ, Royle L, Mimura Y, Kimura Y, Sim RB, Inoges S, Rodriguez-Calvillo M, Zabalegui N, de Cerio AL, Potter KN, Mockridge CI, Dwek RA, Bendandi M, Rudd PM, Stevenson FK (2007) Human follicular lymphoma cells contain oligomannose glycans in the antigen-binding site of the B-cell receptor. J Biol Chem 282(10):7405–7415
Raju TS, Briggs JB, Borge SM, Jones AJ (2000) Species-specific variation in glycosylation of IgG: evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics. Glycobiology 10(5):477–486
Rispens T, Meesters J, den Bleker TH, Ooijevaar-De Heer P, Schuurman J, Parren PW, Labrijn A, Aalberse RC (2013) Fc-Fc interactions of human IgG4 require dissociation of heavy chains and are formed predominantly by the intra-chain hinge isomer. Mol Immunol 53(1–2):35–42. https://doi.org/10.1016/j.molimm.2012.06.012
Rispens T, Davies AM, Ooijevaar-de Heer P, Absalah S, Bende O, Sutton BJ, Vidarsson G, Aalberse RC (2014) Dynamics of inter-heavy chain interactions in human immunoglobulin G (IgG) subclasses studied by kinetic Fab arm exchange. J Biol Chem 289(9):6098–6109. https://doi.org/10.1074/jbc.M113.541813
Roberts GD, Johnson WP, Burman S, Anumula KR, Carr SA (1995) An integrated strategy for structural characterization of the protein and carbohydrate components of monoclonal antibodies: application to anti-respiratory syncytial virus MAb. Anal Chem 67(20):3613–3625. https://doi.org/10.1021/ac00116a001
Robinson NE, Robinson AB (2001) Deamidation of human proteins. Proc Natl Acad Sci U S A 98(22):12409–12413. https://doi.org/10.1073/pnas.221463198
Rouet R, Lowe D, Christ D (2014) Stability engineering of the human antibody repertoire. FEBS Lett 588(2):269–277. https://doi.org/10.1016/j.febslet.2013.11.029
Santos J, Pujols J, Pallares I, Iglesias V, Ventura S (2020) Computational prediction of protein aggregation: advances in proteomics, conformation-specific algorithms and biotechnological applications. Comput Struct Biotechnol J 18:1403–1413. https://doi.org/10.1016/j.csbj.2020.05.026
Sheeley DM, Merrill BM, Taylor LC (1997) Characterization of monoclonal antibody glycosylation: comparison of expression systems and identification of terminal alpha-linked galactose. Anal Biochem 247(1):102–110
Sinha S, Zhang L, Duan S, Williams TD, Vlasak J, Ionescu R, Topp EM (2009) Effect of protein structure on deamidation rate in the Fc fragment of an IgG1 monoclonal antibody. Protein Sci 18(8):1573–1584. https://doi.org/10.1002/pro.173
Stadlmann J, Pabst M, Kolarich D, Kunert R, Altmann F (2008) Analysis of immunoglobulin glycosylation by LC-ESI-MS of glycopeptides and oligosaccharides. Proteomics 8(14):2858–2871. https://doi.org/10.1002/pmic.200700968
Strohl WR (2018) Current progress in innovative engineered antibodies. Protein Cell 9(1):86–120. https://doi.org/10.1007/s13238-017-0457-8
Sydow JF, Lipsmeier F, Larraillet V, Hilger M, Mautz B, Molhoj M, Kuentzer J, Klostermann S, Schoch J, Voelger HR, Regula JT, Cramer P, Papadimitriou A, Kettenberger H (2014) Structure-based prediction of asparagine and aspartate degradation sites in antibody variable regions. PLoS One 9(6):e100736. https://doi.org/10.1371/journal.pone.0100736
Takeuchi M, Takasaki S, Miyazaki H, Kato T, Hoshi S, Kochibe N, Kobata A (1988) Comparative study of the asparagine-linked sugar chains of human erythropoietins purified from urine and the culture medium of recombinant Chinese hamster ovary cells. J Biol Chem 263(8):3657–3663
Tang L, Sundaram S, Zhang J, Carlson P, Matathia A, Parekh B, Zhou Q, Hsieh MC (2013) Conformational characterization of the charge variants of a human IgG1 monoclonal antibody using H/D exchange mass spectrometry. MAbs 5(1):114–125. https://doi.org/10.4161/mabs.22695
Tangvoranuntakul P, Gagneux P, Diaz S, Bardor M, Varki N, Varki A, Muchmore E (2003) Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. Proc Natl Acad Sci U S A 100(21):12045–12050
Tao MH, Morrison SL (1989) Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J Immunol 143(8):2595–2601
Tous GI, Wei Z, Feng J, Bilbulian S, Bowen S, Smith J, Strouse R, McGeehan P, Casas-Finet J, Schenerman MA (2005) Characterization of a novel modification to monoclonal antibodies: thioether cross-link of heavy and light chains. Anal Chem 77(9):2675–2682. https://doi.org/10.1021/ac0500582
Tsubaki M, Terashima I, Kamata K, Koga A (2013) C-terminal modification of monoclonal antibody drugs: amidated species as a general product-related substance. Int J Biol Macromol 52:139–147. https://doi.org/10.1016/j.ijbiomac.2012.09.016
van den Eijnden DH, Joziasse DH, Dorland L, van Halbeek H, Vliegenthart JF, Schmid K (1980) Specificity in the enzymic transfer of sialic acid to the oligosaccharide branches of b1- and triantennary glycopeptides of alpha 1-acid glycoprotein. Biochem Biophys Res Commun 92(3):839–845
van der Kant R, Karow-Zwick AR, Van Durme J, Blech M, Gallardo R, Seeliger D, Assfalg K, Baatsen P, Compernolle G, Gils A, Studts JM, Schulz P, Garidel P, Schymkowitz J, Rousseau F (2017) Prediction and reduction of the aggregation of monoclonal antibodies. J Mol Biol 429(8):1244–1261. https://doi.org/10.1016/j.jmb.2017.03.014
Wang W, Singh S, Zeng DL, King K, Nema S (2007) Antibody structure, instability, and formulation. J Pharm Sci 96(1):1–26. https://doi.org/10.1002/jps.20727
Wang X, Das TK, Singh SK, Kumar S (2009) Potential aggregation prone regions in biotherapeutics: a survey of commercial monoclonal antibodies. MAbs 1(3):254–267. https://doi.org/10.4161/mabs.1.3.8035
Wang W, Vlasak J, Li Y, Pristatsky P, Fang Y, Pittman T, Roman J, Wang Y, Prueksaritanont T, Ionescu R (2011) Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies. Mol Immunol 48(6–7):860–866. https://doi.org/10.1016/j.molimm.2010.12.009
Wang X, An Z, Luo W, Xia N, Zhao Q (2018) Molecular and functional analysis of monoclonal antibodies in support of biologics development. Protein Cell 9(1):74–85. https://doi.org/10.1007/s13238-017-0447-x
Wei B, Berning K, Quan C, Zhang YT (2017) Glycation of antibodies: modification, methods and potential effects on biological functions. MAbs 9(4):586–594. https://doi.org/10.1080/19420862.2017.1300214
Wypych J, Li M, Guo A, Zhang Z, Martinez T, Allen MJ, Fodor S, Kelner DN, Flynn GC, Liu YD, Bondarenko PV, Ricci MS, Dillon TM, Balland A (2008) Human IgG2 antibodies display disulfide-mediated structural isoforms. J Biol Chem 283(23):16194–16205. https://doi.org/10.1074/jbc.M709987200
Xie H, Chakraborty A, Ahn J, Yu YQ, Dakshinamoorthy DP, Gilar M, Chen W, Skilton SJ, Mazzeo JR (2010) Rapid comparison of a candidate biosimilar to an innovator monoclonal antibody with advanced liquid chromatography and mass spectrometry technologies. MAbs 2(4):379–394. https://doi.org/10.4161/mabs.11986
Xu Y, Wang D, Mason B, Rossomando T, Li N, Liu D, Cheung JK, Xu W, Raghava S, Katiyar A, Nowak C, Xiang T, Dong DD, Sun J, Beck A, Liu H (2019) Structure, heterogeneity and developability assessment of therapeutic antibodies. MAbs 11(2):239–264. https://doi.org/10.1080/19420862.2018.1553476
Yin S, Pastuskovas CV, Khawli LA, Stults JT (2013) Characterization of therapeutic monoclonal antibodies reveals differences between in vitro and in vivo time-course studies. Pharm Res 30(1):167–178. https://doi.org/10.1007/s11095-012-0860-z
Yu L, Vizel A, Huff MB, Young M, Remmele RL Jr, He B (2006) Investigation of N-terminal glutamate cyclization of recombinant monoclonal antibody in formulation development. J Pharm Biomed Anal 42(4):455–463. https://doi.org/10.1016/j.jpba.2006.05.008
Zhang Q, Flynn GC (2013) Cysteine racemization on IgG heavy and light chains. J Biol Chem 288(48):34325–34335. https://doi.org/10.1074/jbc.M113.506915
Zhang B, Yang Y, Yuk I, Pai R, McKay P, Eigenbrot C, Dennis M, Katta V, Francissen KC (2008) Unveiling a glycation hot spot in a recombinant humanized monoclonal antibody. Anal Chem 80(7):2379–2390. https://doi.org/10.1021/ac701810q
Zhang Q, Schenauer MR, McCarter JD, Flynn GC (2013) IgG1 thioether bond formation in vivo. J Biol Chem 288(23):16371–16382. https://doi.org/10.1074/jbc.M113.468397
Zhao W, Zhang J, Lu Y, Wang R (2001) The vasorelaxant effect of H(2)S as a novel endogenous gaseous K(ATP) channel opener. EMBO J 20(21):6008–6016. https://doi.org/10.1093/emboj/20.21.6008
Zhu A, Hurst R (2002) Anti-N-glycolylneuraminic acid antibodies identified in healthy human serum. Xenotransplantation 9(6):376–381
Zhu D, McCarthy H, Ottensmeier CH, Johnson P, Hamblin TJ, Stevenson FK (2002) Acquisition of potential N-glycosylation sites in the immunoglobulin variable region by somatic mutation is a distinctive feature of follicular lymphoma. Blood 99(7):2562–2568
Zhu D, Ottensmeier CH, Du MQ, McCarthy H, Stevenson FK (2003) Incidence of potential glycosylation sites in immunoglobulin variable regions distinguishes between subsets of Burkitt’s lymphoma and mucosa-associated lymphoid tissue lymphoma. Br J Haematol 120(2):217–222
Acknowledgments
Pauline M Rudd acknowledges Waters Corporation for research funding and donation of equipment.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Ethics declarations
Conflict of Interest
Yusuke Mimura, Radka Saldova, Yuka Mimura-Kimura, Pauline M Rudd and Roy Jefferis declare that they have no conflict of interest.
Ethical Approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Rights and permissions
Copyright information
© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Mimura, Y., Saldova, R., Mimura-Kimura, Y., Rudd, P.M., Jefferis, R. (2021). Micro-Heterogeneity of Antibody Molecules. In: Pezer, M. (eds) Antibody Glycosylation. Experientia Supplementum, vol 112. Springer, Cham. https://doi.org/10.1007/978-3-030-76912-3_1
Download citation
DOI: https://doi.org/10.1007/978-3-030-76912-3_1
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-76911-6
Online ISBN: 978-3-030-76912-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)